Umecrine Cognition Ab

Maja Johansson

Magnus Doverskog

Thomas Meijer

Paul Alhadeff

Nicolaas Schipper

Torbjörn Bäckström

Pontus Wasling

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

The present invention is directed to a novel pharmaceutical formulation comprising 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.

Pharmaceutical formulation of 3&#x3b1;-ethynyl-3&#x3b2;-hydroxyandrostan-17-one oxime

There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3&#x3b1;-ethynyl-3&#x3b2;-hydroxy-5&#x3b1;-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

Growing community of inventors

Vannas, Sweden

Maja Johansson